EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cardiometabolic Biomarkers for Disease Severity Prediction in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Jee-Fu Huang iD, Chi-Yi Chen, Ming-Jong Bair iD, Tzu-Chun Lin, Ming-Lun Yeh iD, Pei-Chien Tsai iD, Yu-Ju Wei, Chih-Wen Wang, Po-Chen Liang iD, Ming-Yen Hsieh, Mei-Hsuan Lee, Chia-Yen Dai iD und 3 weitere

The Kaohsiung Journal of Medical Sciences · 13.07.2026

DOI: 10.1002/kjm2.70261 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Kaohsiung Journal of Medical Sciences, online erschienen am 13.07.2026. Verfasst von Jee-Fu Huang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kaohsiung Medical University Hospital, Kaohsiung Medical University, Ministry of Health and Welfare, Taiwan..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The impacts of cardiometabolic risk factors (CMRFs) and the biomarkers on disease severity in metabolic dysfunction‐associated steatotic liver disease (MASLD) remain elusive. Accordingly, a multicenter study by recruiting MASLD patients from a nationwide registry database was conducted with a total of 2882 MASLD patients (54.1% males, mean age = 55.6 ± 13.9 years, mean body mass index [BMI] = 28.1 ± 4.9 kg/m 2 ) being recruited. The proportions of patients carrying CMRFs of overweight/obesity, hypertension, hypertriglyceridemia, low high‐density lipoprotein cholesterol level, and diabetes/prediabetes were 91.2%, 74.5%, 54.8%, 59.6%, and 74.5%, respectively. There was a significant linear trend between significant fibrosis and CMRFs (5.1%, 27%, and 54.6% in patients with one CMRF, 3 CMRFs, and ≥ 4 CMRFs, respectively, p = 0.009). The adjusted odds ratios (aOR) with 95% confidence intervals (CIs) for advanced fibrosis in patients of hemoglobin A1c (HbA1c) 5.7%–6.5%, 6.5%–8.0%, and > 8.0% were 1.02 (95% CI = 0.68–1.53, p = 0.93), 1.83 (95% CI = 1.16–2.88, p = 0.01), and 2.78 (95% CI = 1.45–5.34, p = 0.002), respectively. The significant risk factors for advanced fibrosis in MASLD were age > 60 years (aOR = 12.08, 95% CI = 6.23–23.46, p < 0.001), elevated transaminase level (aOR = 1.06, 95% CI = 1.05–1.09, p < 0.001), and diabetes (aOR = 1.51, 95% CI = 1.02–2.26, p = 0.04). In conclusion, there was a significant linear association between advanced fibrosis and the items of CMRFs. The HbA1c level could serve as a predictive biomarker for advanced fibrosis in MASLD with the implication that diabetes control is mandatory for patients with MASLD.

Schlagwörter

Stichwörter der Autor:innen

biomarkerscardiometabolic risksliver fibrosismetabolic dysfunction‐associated steatotic liver diseasetype 2 diabetes mellitus

Autor:innen und Institutionen

  • Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Center for Metabolic Disorders and Obesity, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Division of Gastroenterology and Hepatology, Department of Medicine, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan.
  • Division of Gastroenterology, Department of Internal Medicine, Taitung Mackay Memorial Hospital, Taitung, Taiwan.
  • Mackay Medical College, New Taipei City, Taiwan.

ORCID-Profile: Jee-Fu Huang, Ming-Jong Bair, Ming-Lun Yeh, Pei-Chien Tsai, Po-Chen Liang, Chia-Yen Dai, Chung-Feng Huang, Ming-Lung Yu, Wan-Long Chuang

Förderung

  • Kaohsiung Medical University Hospital
  • Kaohsiung Medical University
  • Ministry of Health and Welfare, Taiwan.
  • Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University, Kaohsiung from The Featured Areas Research Center Program w…
  • Kaohsiung Medical University Chung-Ho Memorial Hospital

Zitieren

APA

Huang, J. F., Chen, C. Y., Bair, M. J., Lin, T. C., Yeh, M. L., Tsai, P. C., Wei, Y. J., Wang, C. W., Liang, P. C., Hsieh, M. Y., Lee, M. H., Dai, C. Y., Huang, C. F., Yu, M. L., & Chuang, W. L. (2026). Cardiometabolic Biomarkers for Disease Severity Prediction in Metabolic Dysfunction‐Associated Steatotic Liver Disease. The Kaohsiung Journal of Medical Sciences. https://doi.org/10.1002/kjm2.70261

Vancouver

Huang JF, Chen CY, Bair MJ, Lin TC, Yeh ML, Tsai PC, et al. Cardiometabolic Biomarkers for Disease Severity Prediction in Metabolic Dysfunction‐Associated Steatotic Liver Disease. The Kaohsiung Journal of Medical Sciences. 2026. doi:10.1002/kjm2.70261

BibTeX
@article{Huang2026,
  author = {Huang, Jee-Fu and Chen, Chi-Yi and Bair, Ming-Jong and Lin, Tzu-Chun and Yeh, Ming-Lun and Tsai, Pei-Chien and Wei, Yu-Ju and Wang, Chih-Wen and Liang, Po-Chen and Hsieh, Ming-Yen and Lee, Mei-Hsuan and Dai, Chia-Yen and Huang, Chung-Feng and Yu, Ming-Lung and Chuang, Wan-Long},
  title = {Cardiometabolic Biomarkers for Disease Severity Prediction in Metabolic Dysfunction‐Associated Steatotic Liver Disease},
  journal = {The Kaohsiung Journal of Medical Sciences},
  year = {2026},
  doi = {10.1002/kjm2.70261}
}
Kostenlos starten →